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25 (58%) a viral syndrome and 10 (23%) organ dis- 
ease. In group 2, 27 (12%) had a CMV episode, 
6 (22%) viremia, 11 (41%) a viral syndrome, and 
10 (37%) organ disease. Group 3 had no docu- 
mented CMV episodes. The average Length of hospi- 
talization for CMV episodes was 11 days in group I, 
and 2.5 days in group 2. At the end of the study 
51 (74%) patients of group I had a functional graft 
(creatinine clearance >30mLlmin), 8 (12%) had 
severely impaired function (C[ <30 mLlmin), 7 (10%) 
were dead, and 3 (4%) had Lost their graft. The 
corresponding numbers for group 2 were 185 (80%), 
28 (12%), 17 (8%), and for group 3 52 (81%), 4 (6%), 
8 (13%), respectively. OveraLL, 25 transplanted pa- 
tients (6.8%) died during the observation period. 
Conclusions: In our experience, a preemptive 
treatment strategy to address the risk of CMV- 
related morbidity foLLowing renal transplantation 
was associated with a markedly higher incidence of 
CMV episodes in the high-risk group as compared to 
the intermediate-risk group. CMV episodes resulted 
in an average hospitalization Length of 11 days and 
a trend towards an increased toss of graft function 
was noted. Therefore and in the Light of the emer- 
gence of newer oral antivira[ agents with a high 
bioavaiLabiLity such as vaLgancicLovir, the current 
strategy has to be reconsidered. 
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Fatal Epstein-Barr Virus/Vleningoencephalitis in 
a Heart Transplant Recipient 
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Background: Epstein-Barr virus (EBV) meningoen- 
cephatitis is a rare, normaLLy benign, complication 
of infectious mononucleosis. This disease might 
have a more severe outcome in immunosuppressed 
patients. 
Objective: We describe the case of a heart trans- 
plant recipient who died with presumed EBV 
meningoencephatitis. 
Results: A 68 year-oLd man was admitted, 12 years 
after heart transplantation for a cardiomyopathy 
of unknown origin, for dizziness and fatting without 
vertigo or other neuroLogicaL symptoms. 6 years be- 
fore admission he had presented several episodes 
of acute rejection. His immunosuppressive regi- 
men consisted of cyctosporine 75 mg bid and my- 
cophenotate mofeti[ 1250 mg bid. On admission he 
was afebrite and cLinicaL examination was normaL. 
Three days after admission he presented a somno- 
Lence with fever. Cerebrospina[ fluid (CSF) analysis 
revealed Lymphocytic meningitis with 45 [ympho- 
cytes/mm2 and elevated total protein LeveL. An 
EEG was suggestive for associated encephalitis. MRI 
imaging showed no abnormalities except an old is- 
chemic cerebeLLar Lesion. CSF cultures for bacteria 
(incLuding M. tuberculosis) and fungi were nega- 
tive. CSF analysis by PCR was positive for EBV and 
negative for aLL other herpes viruses (HSV-1, HSV-2, 
VZV, CMV, HHV-6), 3C-virus and ToxopLasmosis. EBV 
PCR was also positive on peripheral blood. Im- 
munosuppression was stopped and therapeutic i.v. 
gangicLovir was administered. During the foLLowing 
2 weeks, partial cLinicaL response, EEG improve- 
ment and decrease of EBV copies, both in LCR and 
peripheral blood, were observed. UnfortunateLy 
the cLinicaL condition rapidly degraded thereafter 
and therapeutical retrieval was decided. He died 
secondarily to a bacterial pneumonia. The autopsy 
confirmed the presence of a T-ceLL meningitis but 
no other infectious agents was documented (in- 
cluding rabies and prion disease). At the time of au- 
topsy, no evidence of inflammatory infiltrates, viral 
RNA (LMP) or proteins (EBR) in brain parenchyma 
could be documented. No malignant process could 
be identified. 
Conclusion: Fatal EBV meningoencephaLitis is a 
very rare entity. Despite extensive search for an 
alternative diagnosis to explain the Lymphocytic 
meningoencephaLitis, we could only document a 
concomitant EBV replication, both in the CSF fluid 
and peripheral blood, in this patient. CLinicians 
should be aware of this possible cause of menin- 
goencephaLitis in immunosuppressed patients. 
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Background: In recent years an increasing number 
of cases with BK virus (BKV) associated nephropa- 
thy after renal transplantation were reported from 
several transplant centers. The diagnosis of BKV 
associated nephropathy requires invasive aLLograft 
biopsy sampling; therefore it is not easy to perform 
for aLL patients. Quantitation of BKV DNA Load in 
plasma or urine has a high positive predictive value 
for BKV associated nephropaty. 
Infections in So[id Organ Transp[ant Recipients S21 
Objectives: The aim of this study was to evaluate 
BKV quantitation i urine and plasma samples with 
real-time PCR in renal transplant recipients for 
diagnosing BKV associated nephropathy. 
Methods: We performed PCR assays for BKV DNA 
in plasma and urine samples from three renal a[- 
[ograft recipients with suspected BKV associated 
nephropaty. DNA was extracted with the QIAamp 
blood minikit (Qiagen) from samples. Quantitative 
real-time PCR assays were performed using the 
Rotor-Gene instrument (Corbett Research, Sydney, 
Australia). Standart curves for the quantification 
of BKV were constructed using serial dilutions of 
a p[asmid containing the entire [inearized genome 
of the BK virus Dunlop strain inserted into the Barn 
H1 restriction site of the pBR322 p[asmid (ATCC 
45025). PCR primers for the BKV VP1 gene and 
dual labeled probe at the 5' end with 6-carboxy- 
fluorescein (FAM) and the 3' end with 6-carboxy- 
tetramethy[rhodamine (TAMPA) were used for the 
amplification reactions. To ensure that negative 
results were not due to nonspecific inhibition of 
the PCR, each PCR reaction was spiked with a 
p[asmid containing [ycose 6 phosphate dehydro- 
genase gene and specific primers and dual labeled 
probe at the 5' end with BHQ3 and the 3' end 
with TAMPA were used. Urine samples were also 
analyzed for the presence of BKV inclusion bearing 
Decoy ceils after centrifugation and Papanico[au 
staining. Histopatho[ogica[ examination of a[[ograft 
biopsies were performed for two patients. 
Results: Decoy ceils were found in a[[ urine sam- 
pies analysed. For urine and plasma samples from 
two patients, BKV DNA levels were above sug- 
gested thresholds (10,000,000copies/m[ for urine 
and 10,000copies/m[ for plasma) related with 
BKV associated nephropathy. Histopatho[ogica[ ex- 
amination of a[[ograft biopsies from these pa- 
tients confirmed the presence of BKV associated 
nephropathy. For the other renal a[[ograft recipient 
BKV DNA levels in both plasma and urine samples 
were below thresholds 
Conclusions: Detection of BKV DNA in plasma and 
urine samples by real-time PCR is a rapid and 
easy method and a useful[ too[ for determining the 
course of BKV infections. 
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Background: Invasive funga[ infections (IFI) cause 
considerable mortality in immunocompromised pa- 
tients. Recent developments of antifunga[ drugs 
have significantly improved outcomes, particularly 
regarding Candida and Aspersillus spp. However, 
mucormycosis are not we[[ covered by currently 
licensed drugs. 
Objectives: We report a heart transplant (HTx) 
patient who developed bilateral pulmonary lesions 
4 months after transplantation and 3 weeks after a 
successfully treated relapse of a 1 ° CMV infection 
following donor-recipient mismatch (D+/R-). 
Methods E Results: 4 months after HTx and one re- 
jection episode (ISHLT II) treated with oral steroids; 
a 52 year old male patient was admitted with acute 
thoracic pain and cough. 3 weeks earlier a recur- 
rent 1 ° CMV primary infection had been treated 
preemptive with gancic[ovir i.v. followed by oral 
va[gancic[ovir. Clinical examination revealed slight 
deterioration of genera[ condition, dry cough, 
dyspnea, no fever (leukocyte count 9.6×109/L, 
>90% neutrophi[s, C-reactive protein 201 mg/L). 
Empiric antibiotic treatment with [evofloxacin was 
started after specimens were taken for micro- 
biology studies. CT-scan revealed extensive [eft- 
sided pleura[ effusion and suspicion of pneumonia 
and abscess in the [eft lower lobe. Pleura[ effu- 
sion was drained (pH 7.37, glucose 5.8mmo[/L), 
but no etiology was identified. CT-scans 5 days 
later revealed increasing pulmonary abscess for- 
mation [eft and new lesions right. Needle biopsy 
and culture revealed Clostridium spp and Rhizopus 
spp. Levofloxacin was replaced with i.v. imipenem, 
amikacin, and antimycotic therapy was started 
consisting of oral terbinafin and [ipophi[ic ampho- 
tericin B i.v. In a 2 step procedure, lung lesions 
were resected from lower [eft ([obectomy), and 
after one week, atypically from the right lower 
lobe. Invasive mucormycosis was detected in a[[ 
specimens microbio[ogica[[y and histologically. An- 
tifunga[ regimen was changed to oral posacona- 
zo[e (400 mg p.o bid). Resistance testing revealed 
MIC 1 ug/mL. Further course was uneventful and 
the patient was discharged after 3 weeks for fur- 
ther rehabilitation. At 2 years post-diagnosis, the 
patient is fine without documented recurrence of 
funga[ lesions and posaconazo[e is tolerated we[[. 
